For companies in the biotech space, it’s never been easy to navigate the legal and business risks inherent in a highly ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

Sky Labs' CART-I ring – described as a cardio tracker – achieved 84.6% sensitivity compared to 69.1% for the Apple Watch, ...

The 6th RNA Editing Summit returns to Boston this July, bringing together 60+ experts to propel the next generation of RNA editing therapies for rare and common diseases. With momentum building from ...

This July, the 13 th Tumor Models Summit Boston returns, uniting 180+ preclinical and translational experts from biopharma ...

Roche's decision to invest heavily in the US – along with Novartis' announcement, has come hard on the heels of European ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of ...

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...